Seegene

Seegene Operating Cash Flow

The Operating Cash Flow of Seegene (096530.KQ) as of Nov 11, 2026 is 149.33 B KRW. In the previous year, Operating Cash Flow was 85.39 B KRW — a change of 74.88% (higher).

Operating Cash Flow

149.33 BKRW

YoY

74.88%

Last updated:

Operating Cash Flow of Seegene is 2025 149.33 B KRW. Operating Cash Flow of Seegene was 2024 85.39 B KRW. It decreases by 74.88% higher compared to the previous year.

The Seegene Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
14.01 B KRW
Jan 1, 2019
27.14 B KRW
Jan 1, 2020
383.16 B KRW
Jan 1, 2021
334.02 B KRW
Jan 1, 2022
319.01 B KRW
Jan 1, 2023
94.93 B KRW
Jan 1, 2024
85.39 B KRW
Jan 1, 2025
149.33 B KRW
The Seegene Operating Cash Flow history
YEAROperating Cash FlowYoY
149.33 BKRW+74.88%
85.39 BKRW-10.05%
94.93 BKRW-70.24%
319.01 BKRW-4.50%
334.02 BKRW-12.82%
383.16 BKRW+1,311.74%
27.14 BKRW+93.73%
14.01 BKRW+38.50%
10.12 BKRW-38.91%
16.56 BKRW-638.65%
-3.07 BKRW-145.36%
6.78 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Operating Cash Flow of Seegene is 149.33 B KRW in 2025.

Operating Cash Flow of Seegene changed from 85.39 B KRW to 149.33 B KRW, representing a 74.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Seegene since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Seegene

All Key Metrics — Seegene